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CONCLUSION: Young people are a population whose
dependency level is mainly low or moderate, a fact that
enables—with appropriate but generalised mobilization
(doctor, educator, pharmacist, family)—a smoking cessa-
tion attempt to succeed.
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OBJECTIVE: As part of an environment program 
(outcomes program) on smoking cessation, it seemed
interesting to study young smokers under the age of 25.
METHOD: A special questionnaire was distributed to
them via the “Student” supplement of a French regional
weekly newspaper (Tarn Libre), which they were asked
to return by post. RESULTS: The ﬁrst results concerned
the ﬁrst 50 questionnaires returned. Average age: 17.5
years; average weight: 56 kilos; average height: 1,67m.
In our sample, 92% were students, 86% declared them-
selves to be exposed to other people’s smoke and only
37% said they took part in a sporting activity. Age 
at which tobacco dependency began was 13 years; 
98% smoked cigarettes—versus 2% a cigar or pipe); the
average daily consumption was 10 cigarettes; of these,
65% wished to stop smoking, but only 38% had already
made an attempt at smoking cessation. Only 30%,
however, said that they had been asked spontaneously by
their doctor about their desire to stop smoking (minimum
advice) In the Fagerström test, 48% had low or no depen-
dency; 48% had moderate dependency and only 2% had
heavy dependency. CONCLUSION: This pilot study 
conﬁrmed that tobacco dependency is occurring at an
increasingly early age; that tobacco dependency in young
people is low or moderate, and that there is little 
management of tobacco dependency in young people by
doctors.
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OBJECTIVE: The objective of the health system is to
achieve an efﬁcient and equitable allocation of scarce
health resources. In this study, a particular social welfare
function was used to decide the optimal allocation of
resources between smoking cessation methods (medical
advice, nicotine gum and nicotine patches) for smo-
kers and 20–80mg/day lovastatin (HMG-CoA reductase
inhibitor) for individuals with hypercholesterolemia.
METHODS: Parameter epsilon determining the exact
form of the social welfare function is >0 when society has
aversion to inequality in the distribution of health gains
between two patient groups, while it is equal to 0 when
there is no aversion. This parameter was determined using
a questionnaire to assess preferences concerning the 
efﬁciency-equity trade-off in a group of health mana-
gers. Based on these preferences, a higher priority should
be given to the preventive intervention associated with 
a value of epsilon consistent with that from the social
welfare function. RESULTS: A value of epsilon = 1.6 was
obtained for the social welfare function. Values of epsilon
obtained for different preventive interventions were
2.9–1.8 for medical advice for smoking cessation and
20–80mg/day lovastatin, 0.9–0.15 for nicotine gum and
20–80mg/day lovastatin, and 0 for nicotine patch 
for smoking cessation and 20–80mg/day lovastatin. The
highest value of epsilon was obtained for the interven-
tion using medical advice for smoking cessation and 
20mg/day lovastatin for hypercholesterolemia, with 2.9
in men and 2.4 in women. A higher priority should 
be given to the intervention using medical advice for
smoking cessation and 20–80mg/day lovastatin for
hypercholesterolemia than to interventions using nicotine
substitution therapies and 20–80mg/day lovastatin.
CONCLUSION: Lovastatin treatment of hypercholes-
terolemia should have a higher priority than nicotine 
substitution therapies for smoking cessation based on
cost-effectiveness and the social welfare function.
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OBJECTIVES: New treatment recommendations 
describe aggressive lipid-lowering goals to maximize 
cardiovascular-event risk reduction for a broad popula-
tion. This analysis determined what statin doses would
be required to achieve treatment goals in a Canadian
population. METHODS: Canadian treatment guidelines
were reviewed and combined with population-based data
on blood lipid levels to determine the percentage reduc-
tion in LDL-C required to achieve treatment goals. Efﬁ-
cacy of statins was determined from the literature. The
statin dose required for patients to achieve LDL-C reduc-
tion goal was reported. RESULTS: The Canadian
1985–1990 Heart Health Surveys reported that 18% of
men and 17% of women had high blood lipid levels, with
a total cholesterol £6.2mmol/L (corresponding to an
approximate LDL-C level £4.7mmol/L). Canadian 
guidelines dictate that adults with very high risk of car-
diovascular events (those with a history of cardio-
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vascular disease or diabetes) should have LDL-C levels
<2.5mmol/L. Canadians at very high risk and with high
blood lipid levels would require an LDL-C reduction of
at least 47% to achieve treatment goal. Of marketed
statins, only moderate to high doses of atorvastatin (20,
40 and 80mg), simvastatin (80mg) or lovastatin (80mg)
could achieve the LDL-C reduction required by Canadian
guidelines. In contrast, a new lipid-lowering agent (rosu-
vastatin) could achieve a 47% LDL-C reduction at the 
10mg dose. CONCLUSIONS: A signiﬁcant proportion 
of Canadians should receive aggressive lipid-lowering
therapy, which can only be achieved with higher doses of
currently marketed statins to achieve Canadian treatment
goals. Newer statins such as rosuvastatin would assist in
achieving the updated treatment goals. By achieving these
targets at lower doses, rosuvastatin can improve ease and
success of management of hyperlipidemia.
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OBJECTIVE: The aim of this study was to evaluate inter-
vention of drug treatment to elderly patients with car-
diovascular diseases living in nursing homes and assess
the effect of this intervention. METHOD: Eighty patients
living in nursing homes in the County of Stockholm were
randomized into 2 groups, 43 to the intervention group
(average age 87 years) and 37 to the control group
(average age 85 years). Patients included had diagnoses
of heart failure, post myocardial infarction or cardiac
valvular disease. Patients with drug treatment related 
to these diagnoses were also included. At a ﬁrst visit a
research nurse interviewed each patient to collect data of
symptoms and health-related quality of life. The drug
therapy was recorded. After reviewing medication, spe-
cialists in clinical pharmacology and cardiology suggested
changes in the cardiovascular drug therapy to the respon-
sible physician. At each following visit the current drug
therapies as well as data of symptoms and health-related
quality of life were recorded. RESULTS: The outcome
was measured as scores of symptoms. Changes of total
Health Index, ADL scores and deaths were recorded 
as well. The patients in the intervention group initially
consumed 9.8 drugs on the average. For the control 
group this ﬁgure was 9.2 drugs. A change of cardiovas-
cular drug therapy was suggested for 40 patients. Thirty-
two changes in 19 patients were carried out, mainly
regarding furosemide and potassium. Suggestions to ini-
tiate treatment with ACE-inhibitors were never followed.
There were no signiﬁcant changes in the scores of symp-
toms, total Health Index or ADL scores. CONCLU-
SIONS: The self-reported symptoms for each patient were
helpful as a guide for the specialists to evaluate the drug
therapy. The intervention resulted in reduction of drug
use in half of the patients in the intervention group
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OBJECTIVES: U.S. studies using varying methodologies
have reported different estimates for the indirect cost per
person with IBD. Our analysis contributes to this litera-
ture, by using the 1999 sample of the National Health
Interview Survey (NHIS) to estimate the employment
effect of Inﬂammatory Bowel Disease (IBD) in the United
States. METHODS: Our predictive analysis adapts the
theory of labor supply to a health context. A weighted
logistic regression model was used to estimate the odds
ratio (OR) of being out of the labor force as determined
by predictive variables including having been diagnosed
with IBD, with or without symptoms. Controls included
demographic variables and health status indicators. For
those people in the labor force, a second analysis was 
performed to determine whether an individual worked
throughout the entire duration of the past 12 months or
less than 12 months. SUDAAN 8.0 was used to generate
population estimates, systematically correcting for survey
design. RESULTS: Thirty-one and one-half percent of
IBD patients who had experienced symptoms in the past
12 months reported being out of the labor force with OR
= 2.07. We estimated the excess in the non-participation
rate attributable to IBD with symptoms in the past 12
months in the United States to be 11.7%. Based on this,
the indirect cost of non-participation attributable to IBD
in 1998 was $3.5 billion US dollars or $4973 per person
with IBD and symptoms. According to the second
weighted logistic regression, having IBD had no associa-
tion with the duration of work, for those who are in the
labor force. Consequently, the indirect cost of IBD
reported can be interpreted as the indirect cost of IBD
associated with employment losses. CONCLUSIONS: By
using directly observed data in our analysis, this method
of estimation can be used to predict the overall paid-
employment burden of IBD.
